Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled high-molecular-weight heparin for hospitalized adults with mild hypoxemic COVID-19 pneumonia
RBR-7y8j2bsPhase 2Not yet recruiting
- Sponsor
- UNESP Botucatu Medical School
- Start
- Jun 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of heparin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by UNESP Botucatu Medical School. Planned start Jun 2021; status: not yet recruiting.
02
Drugs
heparin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on RBR-7y8j2bs.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7y8j2bs.